The Growing Threat to Human Health: Antibiotic-Resistant Bacteria

Author: Deva Rea, MPH, BSN, BS, RN, CIC

Categories: Antibiotic Stewardship April 5, 2017
SuperbugEnterobac_Website

In February, the World Health Organization (WHO) published their first list of antibiotic-resistant “priority pathogens”. This is a list of the most concerning bacteria that pose the “greatest threat to human health”. This list is divided into three levels of antibiotic-resistant bacteria based on their significance and potential impact to global health. The priority levels are listed as Priority 1 ‘Critical’, Priority 2 ‘High’ and Priority 3 ‘Medium’. Priority 1 (or ‘Critical’) is the most worrisome. It includes antibiotic-resistant Acinetobacter, Pseudomonas and various Enterobacteriaceae (including Klebsiella, Escherichia coli, Serratia, and Proteus species). These antibiotic-resistant gram-negative bacteria can cause serious infections, such as pneumonia and bloodstream infections, leading to significant morbidity and mortality.¹

Priority One: A Deeper Dive into Enterobacteriaceae:

Enterobacteriaceae are a group of bacteria that usually reside in the human gut. They have been watched carefully in recent years due to their significant multidrug resistance. This includes the difficult to treat Carbapenem resistant Enterobacteriaceae (CRE), which is resistant to ß-lactam (beta-lactam) antibiotics, including the “last line” carbapenem antibiotics. And, most recently in the US with the emergence of colistin resistance, which comes from a gene called the MCR-1 gene. Colistin is a “last-resort” antibiotic used to treat patients with multidrug-resistant infections such as CRE. The Centers for Disease Control and Prevention (CDC) states that CRE can contribute to death in up to 50% of patients who become infected.² And with colistin resistance, the outlook is even more ominous.

Even more concerning is the increase of multidrug resistance in children. A recent study looked at children under 18 years of age that were diagnosed with an Enterobacteriaceae-associated infection between January 1, 2007 and March 31, 2015. They reviewed data from 48 hospitals and about 94,000 children. The report showed a significant increase in MDR-GNE (Multidrug-resistant Gram-negative enteric Enterobacteriaceae) diagnosis with an Enterobacteriaceae-associated infection (0.2% in 2007 to 1.5% by 2015). This is an increase of more than 700%, with 23% of these infections defined as nosocomial (hospital acquired).³

Prevention of antibiotic resistance:

Antibiotic-resistant organisms such as CRE are increasing globally across all patient types. Prevention of antibiotic resistance is key! The CDC suggests five steps to slow global antibiotic resistance:

  1. “Awareness and education:Raising public awareness about this threat is an important first step.”
  2. “Surveillance:Countries need systems to track antimicrobial resistance and share findings with international partners.”
  3. “Infection, prevention and control:Infection control and hygiene are critical to stopping spread of resistant germs in healthcare settings.” [Infection control practices such as good hand hygiene, isolation precautions, and environmental cleaning/disinfection are critical in stopping transmission of multi-drug resistant organisms (MDROs). Typically patients with MDROs such as CRE are placed on standard and contact isolation precautions (use gowns and gloves) to prevent the transmission of these resistant organisms.]
  4. “Optimize use:Ensuring that antibiotics are still effective in the future requires that they be used correctly today.” [This includes antibiotic use in food supplies.]
  5. “R&D and investment:Research and development of new drugs, diagnostic tools and vaccines are a global priority.”⁴

These five steps highlight the importance of antibiotic stewardship, surveillance, infection prevention and the development of new antibiotics to combat the growing pandemic of antibiotic-resistant organisms. With careful attention to these priorities, the forecast for antibiotic-resistant bacteria such as CRE, becomes more optimistic.

¹World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Feb 2017. Available from: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/

²The Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Enterobacteriaceae in Healthcare Settings. Last updated March 2016. Available from https://www.cdc.gov/hai/organisms/cre/

³Sharon B. Meropol, Allison A. Haupt, Sara M. Debanne; Incidence and Outcomes of Infections Caused by Multidrug-Resistant Enterobacteriaceae in Children, 2007–2015. J Pediatric Infect Dis Soc 2017 piw093. doi: 10.1093/jpids/piw093

⁴The Centers for Disease Control and Prevention (CDC). International Activities to Combat AR. Last updated Jan 2017. Available from: https://www.cdc.gov/drugresistance/us-activities/national-strategy.html

Author

Deva Rea MPH, BSN, BS, RN, CIC
deva Clinical Science Liaison, PDI Ohio Valley Region

Profile

Deva Rea’s passion for infection prevention and epidemiology began while studying for her MPH. Prior to her role in epidemiology at a local health department, she worked a nurse in various specialties.

While in infection prevention, Deva cultivated her skills and combined her vast educational background to help improve patient outcomes and advance the practice of infection prevention. She has been in the healthcare industry for over 15 years, speaking at many conferences, including national APIC. Deva is dedicated to spreading knowledge and will continue to be a strong advocate for patients and the field of infection prevention/ epidemiology.

Deva is currently a Clinical Science Liaison (CSL) supporting the Ohio Valley Region.

Contact

Phone: 702-283-5417
Company Website: Pdihc.com
Email: Deva.rea@pdihc.com

Hobbies

Yoga
Travel
Art & cultural events

EDUCATION

University of South Florida
Master of Public Health in Tropical Public Health/ Communicable Diseases (Epidemiology)
Graduate Certificate in Infection Control

University of Central Florida
Bachelor of Science in Nursing
Bachelor of Science in Microbiology and Molecular Biology

Certification
Registered Nurse
Certification Board of Infection Control (CBIC)- CIC

Why I love what I do

‘Bugs’ are pretty cool! How microbes operate and survive has always amazed me. Understanding how this microbial world exists and our role in it has been a lifelong passion. From biofilms to the microbiome, the complexity of something we can’t see with the naked eye is a remarkable phenomenon. Being able to offer guidance and support to others in infection prevention and epidemiology is wonderful. Overall, helping prevent infections in healthcare is why I love doing what I do!

Areas of Expertise

Infection prevention and control
Epidemiology
Micro/ molecular biology
Infectious diseases and transmission
Environmental disinfection
Healthcare associated infections
Education

More about Deva Rea Less about Deva Rea